Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab. (PubMed, Neurol Int) - Sep 25, 2026 - "Both antibodies substantially reduce amyloid and modestly slow average clinical decline in selected patients, but neither restores lost function, greater amyloid clearance does not establish greater individual benefit, and cross-trial superiority cannot be inferred. Treatment requires biomarker-guided selection, APOE-informed risk counseling, serial MRI, infusion and ARIA-management capacity, and shared decision-making that incorporates cost, access, and patient/caregiver burden."
Journal • Review • Alzheimer's Disease • CNS Disorders • APOE
|
|
Fatmanur Karaku? Dilbaz; Ülkü Figen Demir
|